Marshall Wace’s Astria Therapeutics ATXS Stock Holding History

Marshall Wace’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-405,700	Closed	-$5.31M	–	3183
2025 Q4	$5.31M	Buy	+405,700	New	+$4.85M	﹤0.01%	1129
2024 Q2	–	Sell	-70,241	Closed	-$989K	–	2531
2024 Q1	$989K	Buy	70,241 +55,941	+391%	+$697K	﹤0.01%	1657
2023 Q4	$110K	Buy	+14,300	New	+$79.1K	﹤0.01%	2035
2023 Q2	–	Sell	-30,994	Closed	-$412K	–	2454
2023 Q1	$412K	Buy	30,994 +16,045	+107%	+$217K	﹤0.01%	2178
2022 Q4	$223K	Buy	+14,949	New	+$154K	﹤0.01%	2670

Marshall Wace's ATXS Position: Q1 2026 in Review

Marshall Wace sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 405,700 shares — an estimated $5.31M sold.

Marshall Wace first reported a position in ATXS in Q4 2022 and held it in 5 quarters. The position peaked at $5.31M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Marshall Wace reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Marshall Wace sold 405,700 Astria Therapeutics shares in Q1 2026, an estimated $5.31M.
Marshall Wace first reported a position in Astria Therapeutics in Q4 2022 and held it in 5 quarters.
Marshall Wace's Astria Therapeutics position peaked at $5.31M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.